Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.
作者信息
Brandenburg Vincent, Heine Gunnar H, Marx Nikolaus, Stöhr Robert
机构信息
Rhein-Maas-Klinikum, Würselen, Germany.
AGAPLESION MARKUS KRANKENHAUS, Frankfurt am Main, Germany.
出版信息
Clin Res Cardiol. 2020 Oct;109(10):1316-1318. doi: 10.1007/s00392-020-01630-z. Epub 2020 Mar 25.
Abstract
摘要
相似文献
1
Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.静脉注射铁剂后FGF23和低磷血症的急剧升高不会导致心肌损伤。
Clin Res Cardiol. 2020 Oct;109(10):1316-1318. doi: 10.1007/s00392-020-01630-z. Epub 2020 Mar 25.
2
High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.高剂量羧基麦芽糖铁用于射血分数降低的心力衰竭患者时会导致明显的低磷血症。
J Am Coll Cardiol. 2018 May 15;71(19):2270-2271. doi: 10.1016/j.jacc.2018.03.448.
3
Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.布罗索尤单抗在难治性铁诱导的成纤维细胞生长因子23介导的低磷性骨软化症中的新用途。
Rheumatology (Oxford). 2020 Aug 1;59(8):2166-2168. doi: 10.1093/rheumatology/kez627.
4
Randomized trial of intravenous iron-induced hypophosphatemia.静脉铁诱导低磷血症的随机试验。
JCI Insight. 2018 Dec 6;3(23):124486. doi: 10.1172/jci.insight.124486.
5
A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure.缺铁性心力衰竭患者静脉铁剂治疗的Meta分析
Am J Cardiol. 2021 Feb 15;141:152-153. doi: 10.1016/j.amjcard.2020.11.025. Epub 2020 Nov 29.
6
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.因使用羧基麦芽糖铁导致的基于成纤维细胞生长因子23的严重低磷性骨软化症。
BMJ Case Rep. 2018 Jan 3;2018:bcr-2017-222851. doi: 10.1136/bcr-2017-222851.
7
Case report: A rare cause of severe hypophosphatemia.病例报告：严重低磷血症的罕见病因。
Ann Endocrinol (Paris). 2020 Jun;81(2-3):125-126. doi: 10.1016/j.ando.2020.04.008. Epub 2020 May 4.
8
[Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].[低磷血症，静脉使用铁剂鲜为人知的不良反应]
Med Clin (Barc). 2014 Sep 15;143(6):284-5. doi: 10.1016/j.medcli.2013.11.030. Epub 2014 Jan 22.
9
FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.静脉注射聚麦芽糖铁后FGF23升高与低磷血症：一项前瞻性研究。
J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7. doi: 10.1210/jc.2008-2396. Epub 2009 Apr 14.
10
Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.一名稳定的肾移植受者静脉注射羧基麦芽糖铁后发生严重低磷血症。
Transplantation. 2010 Oct 15;90(7):804-5. doi: 10.1097/TP.0b013e3181f00a18.
引用本文的文献
1
The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia.静脉注射铁剂对缺铁但无贫血的慢性肾脏病患者肾损伤及功能标志物的影响
Kidney Int Rep. 2021 Nov 24;7(2):322-326. doi: 10.1016/j.ekir.2021.11.002. eCollection 2022 Feb.
2
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review.低磷血症、成纤维细胞生长因子23与第三代静脉铁剂：一篇叙述性综述
Drugs Context. 2021 Jan 19;10. doi: 10.7573/dic.2020-11-3. eCollection 2021.
本文引用的文献
1
Circulatory factors associated with function and prognosis in patients with severe heart failure.与严重心力衰竭患者功能和预后相关的循环因素。
Clin Res Cardiol. 2020 Jun;109(6):655-672. doi: 10.1007/s00392-019-01554-3. Epub 2019 Sep 27.
2
Heart rate, mortality, and the relation with clinical and subclinical cardiovascular diseases: results from the Gutenberg Health Study.心率、死亡率与临床和亚临床心血管疾病的关系：来自古腾堡健康研究的结果。
Clin Res Cardiol. 2019 Dec;108(12):1313-1323. doi: 10.1007/s00392-019-01466-2. Epub 2019 Apr 5.
3
Plasma FGF23 does not rise during physical exercise as a physiological model of sympathetic activation.作为交感神经激活的生理模型，在体育锻炼期间血浆成纤维细胞生长因子23（FGF23）不会升高。
Clin Res Cardiol. 2019 Mar;108(3):341-343. doi: 10.1007/s00392-018-1347-7. Epub 2018 Aug 8.
4
High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.高剂量羧基麦芽糖铁用于射血分数降低的心力衰竭患者时会导致明显的低磷血症。
J Am Coll Cardiol. 2018 May 15;71(19):2270-2271. doi: 10.1016/j.jacc.2018.03.448.
5
Longitudinal FGF23 Trajectories and Mortality in Patients with CKD.慢性肾脏病患者的成纤维细胞生长因子 23 纵向轨迹与死亡率。
J Am Soc Nephrol. 2018 Feb;29(2):579-590. doi: 10.1681/ASN.2017070772. Epub 2017 Nov 22.
6
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.成纤维细胞生长因子23直接作用于肝细胞以促进慢性肾脏病中的炎症反应。
Kidney Int. 2016 Nov;90(5):985-996. doi: 10.1016/j.kint.2016.05.019. Epub 2016 Jul 22.
7
FGF23 induces left ventricular hypertrophy.成纤维细胞生长因子 23 可诱导左心室肥厚。
J Clin Invest. 2011 Nov;121(11):4393-408. doi: 10.1172/JCI46122. Epub 2011 Oct 10.
8
Ferric carboxymaltose in patients with heart failure and iron deficiency.缺铁性心力衰竭患者的羧基麦芽糖铁。
N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.
9
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.成纤维细胞生长因子23与接受血液透析患者的死亡率
N Engl J Med. 2008 Aug 7;359(6):584-92. doi: 10.1056/NEJMoa0706130.
Zotero 插件